For your HLA-B*5701–negative patients with HIV-1...
TRIUMEQ—with the Power of DOLUTEGRAVIR AT THE CORE
Not an actual patient.
Please see full Prescribing Information, including Boxed Warning and Medication Guide, for TRIUMEQ.
- Walmsley S, Baumgarten A, Berenguer J, et al. Dolutegravir plus abacavir/lamivudine for the treatment of HIV-1 infection in antiretroviral therapy-naive patients: week 96 and week 144 results from the SINGLE randomized clinical trial. J Acquir Immune Defic Syndr. 2015;70(5):515-519.
- Data on file. ViiV Healthcare group of companies. Research Triangle Park, NC.
- Min S, Song I, Borland J, et al. Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob Agents Chemother. 2010;54(1):254-258.